News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Invivyd, Inc. - Common Stock
(NQ:
IVVD
)
1.020
-0.130 (-11.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Invivyd, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
September 23, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
September 12, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd to Participate in Upcoming Investor Conferences
September 05, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
September 04, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
September 03, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial
August 27, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 14, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
August 12, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
July 01, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
June 14, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd to Participate at the Jefferies Global Healthcare Conference
June 03, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial
May 31, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
May 31, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
May 29, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Elects Two New Independent Members to its Board of Directors
May 22, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
May 07, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
May 02, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
April 30, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
April 15, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces CEO Transition
April 12, 2024
Jeremy Gowler appointed Interim CEO
From
Invivyd
Via
GlobeNewswire
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
April 04, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
March 28, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
March 22, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
March 22, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
January 03, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
December 18, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
Invivyd
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.